Patent: 10,487,116
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for Patent: 10,487,116
| Title: | Immunotherapy against several tumors, such as lung cancer, including NSCLC |
| Abstract: | A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has glioblastoma and/or gastric cancer. A method of treating a patient who has glioblastoma and/or gastric cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the glioblastoma and/or gastric cancer. |
| Inventor(s): | Weinschenk; Toni (Aichwald, DE), Walter; Steffen (Reutlingen, DE), Fritsche; Jens (Dusslingen, DE), Song; Colette (Ostfildern, DE), Singh; Harpreet (Munich, DE) |
| Assignee: | IMMATICS BIOTECHNOLOGIES GMBH (Tuebingen, DE) |
| Application Number: | 16/369,905 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,487,116
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | 02/26/2004 | See Plans and Pricing | 2033-08-05 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
